NCT07375693Enrolling by invitationPhase 2
Effect of Melatonin on Oxidative Stress Parameters in Levodopa-Treated Parkinson's Disease Patients
Effect of Melatonin on Oxidative Stress Parameters in Levodopa-Treated Parkinson's Disease Patients: A Randomized, Double-Blind, Placebo-Controlled Trial.
Source: ClinicalTrials.gov · Last updated 29 Jan 2026
Brief summary (registry, in English)
In Bangladesh Melatonin is currently used for insomnia. Its potential therapeutic benefits beyond sleep regulation. This study aimss to evaluate the effects of melatonin supplementation on oxidative stress markers, neuroinflammation and clinical outcomes in patients with Parkinson's disease. The main question it aims to answer: In patients with Parkinson's disease receiving levodopa, does melatonin supplementation, compared to levodopa treatment alone, improve the symptoms of PD over a 12 week of period. Participants will: Take Melatonin 10mg or placebo everyday for 3 months at night 30minutes before bedtime. Visit the clinic once every 6 weeks for checkups and tests keep a diary of their symptoms,UPDRS score. At the end of 12 weeks will reaper hs-CRP, MDA and GSH.
- Status (registry)
- Enrolling by invitation
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- First submitted
- 10 Dec 2025
- Start date
- 17 Feb 2026
- Primary completion date
- 23 Aug 2026
- Lead sponsor
- Bangladesh Medical University
- Diseases
- Parkinson disease
- NCT number
- NCT07375693
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 70
- From 17 Feb 2026 to the primary completion date, 23 Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior stereotactic surgery for PD
Other illness
- suffering from active malignancy
- known hypersensitivity to melatonin
- pt with autoimmune disease
- has any clinically significant medical condition that could interfere with the subject's ability to safely participate in the study or to be followed
Other
- secondary causes of PD
- Patients taking anticonvulsants, OCP, DMARD
- pregnancy or lactating mother
Who the study is looking for
- diagnosesd Parkinson's disease patients taking levodopa
- mild to moderate PD pt according to Hohen and Yahr staging, stage-I,II,III
- age:\>45 years
- both male and female
Age in the registry: 45 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Bangladesh Medical University Coordinator of this site? Confirm its status | Dhaka | Bangladesh | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.